AKSOYALP, Z. Ş. Et Al. 2021. Which proteinase-activated receptor-1 antagonist is better?: Evaluation of vorapaxar and parmodulin-2 effects on human left internal mammary artery endothelial function. LIFE SCIENCES , vol.286 .

AKSOYALP, Z. Ş., NACİTARHAN, C., & ERBASAN, O., (2021). Which proteinase-activated receptor-1 antagonist is better?: Evaluation of vorapaxar and parmodulin-2 effects on human left internal mammary artery endothelial function. LIFE SCIENCES , vol.286.

AKSOYALP, ZİNNET, CAHİT NACİTARHAN, And OZAN ERBASAN. "Which proteinase-activated receptor-1 antagonist is better?: Evaluation of vorapaxar and parmodulin-2 effects on human left internal mammary artery endothelial function," LIFE SCIENCES , vol.286, 2021

AKSOYALP, ZİNNET Ş. Et Al. "Which proteinase-activated receptor-1 antagonist is better?: Evaluation of vorapaxar and parmodulin-2 effects on human left internal mammary artery endothelial function." LIFE SCIENCES , vol.286, 2021

AKSOYALP, Z. Ş. NACİTARHAN, C. And ERBASAN, O. (2021) . "Which proteinase-activated receptor-1 antagonist is better?: Evaluation of vorapaxar and parmodulin-2 effects on human left internal mammary artery endothelial function." LIFE SCIENCES , vol.286.

@article{article, author={ZİNNET ŞEVVAL AKSOYALP Et Al. }, title={Which proteinase-activated receptor-1 antagonist is better?: Evaluation of vorapaxar and parmodulin-2 effects on human left internal mammary artery endothelial function}, journal={LIFE SCIENCES}, year=2021}